In this task, you are given a summary for US Congressional and California state bill, your task is to generate a Title for this bill. The preferred titles are under forty words and mention the purpose of the bill.
--------
Question: Presidential Allowance Modernization Act of 2017 (Sec. 2) This bill amends the Former Presidents Act of 1958 to to revise provisions governing the compensation provided to a former President. Each former President shall receive from the United States an annuity of $200,000 per year. The General Services Administration (GSA) is authorized to provide each former President a monetary allowance of $500,000 per year for five years beginning six months after the expiration of his or her term, $350,000 per year for the next five years, and $250,000 per year thereafter.   Such annuity and allowance shall be increased each year by the same percentage as Social Security benefits. Such allowance shall be reduced by the amount the former President's earned income exceeds $400,000. The bill: (1) limits the office staff provided for each former President to not more than 13 individuals, and (2) requires that suitable office space for a former President be provided on a reimbursable basis. The increases from $20,000 per year to $100,000 per year, and provides for cost-of-living adjustments to, the monetary allowance amount for surviving spouses of former Presidents.

Answer: Presidential Allowance Modernization Act of 2017


Question: Verifying Authority and Legality In Drug Compounding Act of 2012 - Amends the Federal Food, Drug, and Cosmetic Act (FFDCA) with respect to the regulation of compounding drugs.

Eliminates authority for compounding pharmacies to: (1) compound drugs before the receipt of a valid prescription order, or (2) compound any drug product that is a copy of a commercially available drug.

Requires the Secretary of Health and Human Services (HHS) to develop, maintain and transmit to the appropriate state agencies a list of drug products that should not be compounded, including: (1) drug products whose compounding is reasonably likely to cause an adverse effect on their safety or effectiveness; and (2) drug products that have been withdrawn or removed from the market because they have been found to be unsafe or not effective.

Authorizes the Secretary to waive the requirement that a drug product must be compounded for an individually identified patient based on a valid prescription order or similar notation if compounding the drug product is necessary to address a drug shortage, or to protect public health or well-being. Prohibits the Secretary from authorizing a state to grant such waivers.

Authorizes the Secretary to waive the requirement that a drug product must be compounded for an individually identified patient based on a valid prescription order or similar notation if the pharmacy or pharmacist: (1) submits a satisfactory application to the Secretary; and (2) agrees to comply with any condition or limitation specified by the Secretary. Makes a pharmacy or pharmacist required to be registered under the FFDCA as a drug producer ineligible for a waiver. Permits the Secretary to authorize a state to grant such waivers applicable to compounded drug products sold or dispensed within the state pursuant to a memorandum of understanding between the Secretary and the state.

Authorizes the Secretary to waive the prohibition against compounding any drug product that is a copy of a commercially available drug if it is necessary to protect public health or well-being. Prohibits the Secretary from authorizing a state to waive such prohibition.

Subjects the facilities of any pharmacy receiving a waiver under this Act to inspection to determine compliance with this Act.

Requires the Secretary to publish notice at least 30 days before cancelling a waiver, unless it is necessary to prevent an adverse impact on public health or safety.

Sets forth a required label statement for any drug compounded pursuant to this Act.

 Requires a pharmacist or physician compounding a drug product to report any adverse event associated with the use of the product within a specified time frame.

Answer: To amend the Federal Food, Drug, and Cosmetic Act to provide for the compounding of drug products.


Question: Bureau Advisory Opinion Act of 2016  This bill amends the Consumer Financial Protection Act of 2010 to require the Consumer Financial Protection Bureau (CFPB) to establish a procedure and promulgate rules to provide written opinions in response to inquiries concerning conformance of specific proposed or prospective conduct by a covered person with federal consumer financial law. A &quot;covered person&quot; under the Act is: (1) any person that engages in offering or providing a consumer financial product or service, and (2) any affiliate of that person if the affiliate acts as a service provider to the person. The CFPB, within 90 days of receiving such a request for an opinion, shall:   issue an opinion stating whether the described conduct would violate federal consumer financial law, deny the request, or explain why it is not feasible to issue an opinion.  The CFPB shall not issue an opinion on a general question of interpretation, a hypothetical situation, conduct of someone other than the requester, or past conduct the covered person doesn't plan to continue.  A request may be withdrawn at any time prior to the CFPB issuing a response. An issued advisory opinion may be amended or revoked at any time.  An opinion rendered pursuant to this bill shall be placed in the CFPB's public record 90 days after the requesting party has received the advice, subject to specified limitations on public disclosure.  Any person may rely on an opinion issued by the CFPB that has not been amended or withdrawn and liability shall not attach to conduct consistent with such opinion.  The CFPB shall implement a system to charge a fee for such inquiries sufficient to pay the costs of carrying out this bill.

Answer:
Bureau Advisory Opinion Act of 2016